Jenkin Kayte A, McAinch Andrew J, Zhang Yuan, Kelly Darren J, Hryciw Deanne H
Centre for Chronic Disease Prevention and Management, College of Health and Biomedicine Victoria University, Melbourne, Vic., Australia.
Clin Exp Pharmacol Physiol. 2015 Mar;42(3):256-62. doi: 10.1111/1440-1681.12355.
Hyperglycaemia increases the risk of developing diabetic nephropathy, with primary targets in the glomerulus and proximal tubule. Importantly, glomerular damage in the kidney leads to elevated albumin levels in the filtrate, which contributes to tubular structural modifications that lead to dysfunction. Diabetes alters the endocannabinoid system in a number of target organs, with previous research characterizing tissue-specific changes in the expression of the cannabinoid receptor 1 (CB1 ) and G protein-coupled receptor 55 (GPR55), a putative cannabinoid receptor, in diabetes. Although these receptors have a functional role in the cannabinoid system in the kidney, there has been little investigation into changes in the expression of CB1 and GPR55 in the proximal tubule under diabetic conditions. In this study, CB1 and GPR55 messenger RNA and protein levels were quantified in cultured human kidney cells and then treated with either elevated glucose, elevated albumin, or a combination of glucose and albumin for 4, 6, 18, or 24 h. In addition, CB1 and GPR55 protein expression was characterized in whole-kidney lysate from streptozotocin-induced diabetic Sprague-Dawley rats. In vitro exposure to elevated glucose and albumin increased CB1 and GPR55 messenger RNA and protein expression in proximal tubule cells in a time-dependant manner. In whole kidney of streptozotocin-induced diabetic rats, CB1 protein was upregulated, whereas GPR55 protein concentration was not altered. Thus, expression of CB1 and GPR55 in proximal tubules is altered in response to elevated levels of glucose and albumin. Further investigations should determine if these receptors are effective physiological targets for the treatment and prevention of diabetic nephropathy.
高血糖会增加患糖尿病肾病的风险,主要靶点是肾小球和近端小管。重要的是,肾脏中的肾小球损伤会导致滤液中白蛋白水平升高,这会导致肾小管结构改变,进而导致功能障碍。糖尿病会改变多个靶器官中的内源性大麻素系统,先前的研究描述了糖尿病中大麻素受体1(CB1)和G蛋白偶联受体55(GPR55,一种假定的大麻素受体)表达的组织特异性变化。尽管这些受体在肾脏的大麻素系统中具有功能作用,但对于糖尿病条件下近端小管中CB1和GPR55表达的变化研究甚少。在本研究中,对培养的人肾细胞中的CB1和GPR55信使核糖核酸及蛋白水平进行了定量,然后用高糖、高白蛋白或糖与白蛋白的组合处理4、6、18或24小时。此外,还对链脲佐菌素诱导的糖尿病Sprague-Dawley大鼠的全肾裂解物中的CB1和GPR55蛋白表达进行了表征。体外暴露于高糖和白蛋白会以时间依赖性方式增加近端小管细胞中CB1和GPR55信使核糖核酸及蛋白的表达。在链脲佐菌素诱导的糖尿病大鼠的全肾中,CB1蛋白上调,而GPR55蛋白浓度未改变。因此,近端小管中CB1和GPR55的表达会因葡萄糖和白蛋白水平升高而改变。进一步的研究应确定这些受体是否是治疗和预防糖尿病肾病的有效生理靶点。